Table 1

Demographics, clinical characteristics, laboratory variables, treatment of patients with ‘near misses’ (n=411) shown separately for failure to reach either CRP, PGA, SJC or TJC criterion; data are also shown for patients in their first Boolean remission visit without having had a preceding near-miss visit. Data are expressed as means (SD), unless indicated otherwise

CRPPGASJCTJCFull remission
Patients, n (%)54 (13.1)249 (60.6)80 (19.5)28 (6.8)119 (16)
SDAI≤3.3, %42.617.77.532.194.1
CDAI≤2.8, %79.616.95.021.491.6
PGA−EGA, mm−1.6 (6.0)26.0 (19.1)−16.5 (14.2)0.3 (4.2)0.2 (5.8)
Age, years55.9 (13.7)55.7 (12.9)55.2 (13.9)52.7 (14.7)54.6 (13.3)
Female, %68.577.582.585.778.2
Duration of disease, years9.1 (10.9)8.7 (10.0)7.7 (8.7)7.3 (9.5)8.3 (10.8)
C-reactive protein, mg/dl2.3 (1.6)0.4 (0.2)0.5 (0.3)0.4 (0.3)0.4 (0.3)
Erythrocyte sedimentation rate, mm/h42.5 (27.4)20.1 (16.3)17.3 (11.1)12.0 (6.8)19.4 (17.0)
Pain by visual analogue scale, mm7.3 (8.9)31.9 (18.8)5.6 (7.9)8.0 (8.3)3.8 (6.8)
Patient global assessment, cm0.4 (0.4)3.6 (1.9)0.4 (0.4)0.4 (0.4)0.3 (0.3)
Evaluator's global assessment, cm0.5 (0.6)1.0 (1.3)2.1 (1.4)0.3 (0.3)0.3 (0.5)
Swollen joint count, 28 joints0.4 (0.5)0.4 (0.5)4.5 (3.1)0.3 (0.5)0.3 (0.5)
Tender joint count, 28 joints0.2 (0.4)0.4 (0.5)0.3 (0.5)3.2 (2.0)0.2 (0.4)
Morning stiffness, minutes8.9 (28.8)17.8 (42.0)20.9 (143.4)15.4 (37.9)8.3 (37.6)
Anti-CCP antibodies, U/ml128.5 (148.3)148.5 (171.4)153.5 (186.1)145.3 (177.9)131.1 (158.3)
Rheumatoid-factor, IU/ml305.3 (557.3)142.2 (308.1)119.3 (258.0)123.7 (185.4)92.5 (192.0)
Anti-CCP antibodies positive, %77.879.188.882.175.6
Rheumatoid-factor positive, %68.566.765.057.157.1
SDAI3.8 (1.9)5.8 (2.9)7.7 (4.3)4.6 (2.3)1.3 (1.1)
CDAI1.5 (1.2)5.3 (2.8)7.3 (4.3)4.2 (2.2)1.0 (1.0)
Disease activity score 282.6 (0.4)2.1 (0.4)2.6 (0.4)2.9 (0.5)1.9 (0.4)
Non-steroidal anti-inflammatory drugs, %59.351.857.539.335
Analgesics, %11.17.62.57.15
Glucocorticoids, %46.340.643.835.732
Synthetic DMARDs, %81.576.377.571.477.3
Biological DMARDs, %18.523.722.528.621.8
  • CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; EGA, evaluator global assessment; PGA, patient global assessment; SDAI, Simplified Disease Activity Index; SJC, swollen joint count; TJC, tender joint count.